The mission of the CMG is to gather data, evaluate, and disseminate methods of genomic medicine implementation across diverse projects conducted by IGNITE members.
The Dissemination, Outreach, and Sustainability (DOS) Working Group identifies network needs and opportunities in the areas of dissemination, outreach, economics, and sustainability. The working group addresses these needs and opportunities through activities including:
It is the vision of the IGNITE Network that significant genomic implementation knowledge gained as a result of the IGNITE NIH/NHGRI funded study be made readily available via the IGNITE website utilizing a “toolbox” approach as demonstrated by other NHGRI network programs. The “tools” provided are intended to assist researchers and healthcare institutions in their assessment and implementation of genomic medicine in an efficient and effective manner.
The Education Working Group will share and disseminate educational resources and strategies and related data from IGNITE Network sites to a) facilitate collaboration and information sharing within the Network; and b) contribute to the evidence base of patient, provider, and student/trainee education supporting clinical implementation of genomic medicine and pharmacogenomics.
To promote the adoption of genomic medicine in practice by identifying and addressing implementation barriers experienced by healthcare providers.
To bring together IGNITE members creating and implementing clinical informatics tools within the network’s genomic medicine demonstration projects; to help support the exchange of information and ideas among members, and to organize clinical informatics dissemination efforts.
Assess, document and publish the clinical validity, clinical utility and health economics to ensure the sustainability of IGNITE projects moving genomic medicine into clinical practice for improving health.
The Pharmacogenetics Interest Group will share and disseminate data from multiple sites implementing pharmacogenomic testing to contribute to the evidence base of metrics and health-related outcomes gained from using pharmacogenomic information in clinical care.